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ABSTRACT: We report on the synthesis, characterization, and
stability studies of new titanocene complexes containing a methyl
group and a carboxylate ligand (mba = −OC(O)-p-C6H4-S−) bound
to gold(I)−N-heterocyclic carbene fragments through the thiolate
group: [(η5-C5H5)2TiMe(μ-mba)Au(NHC)]. The cytotoxicities of the
heterometallic compounds along with those of novel monometallic
gold−N-heterocyclic carbene precursors [(NHC)Au(mbaH)] have
been evaluated against renal, prostate, colon, and breast cancer cell
lines. The highest activity and selectivity and a synergistic effect of the
resulting heterometallic species was found for the prostate and colon
cancer cell lines. The colocalization of both titanium and gold metals
(1:1 ratio) in PC3 prostate cancer cells was demonstrated for the
selected compound 5a, indicating the robustness of the heterometallic
compound in vitro. We describe here preliminary mechanistic data
involving studies on the interaction of selected mono- and bimetallic compounds with plasmid (pBR322) used as a model nucleic
acid and the inhibition of thioredoxin reductase in PC3 prostate cancer cells. The heterometallic compounds, which are highly
apoptotic, exhibit strong antimigratory effects on the prostate cancer cell line PC3.
■ INTRODUCTION
The potential of heterometallic complexes as cancer chemo-
therapeutics has been recently highlighted.1 The improved
activity of heteronuclear complexes as antitumor agents by
incorporation of two different cytotoxic metals within the same
molecule has been demonstrated. The beneficial influence may
be due to a synergistic or cooperative effect. Bimetallic and
trimetallic compounds with anticancer properties have been
described. There have been reports on titanocenes incorporat-
ing Ru(II), Pt(II), and Pd(II) centers2,3 and a number of
complexes containing ferrocene moieties and other metals.4
Bimetallic systems based on Ru(II)−Pt(II)5 or Ru(II)−Ir(III)6
have also been described. Ferrocenyl phosphanes were
incorporated in the iminophosphorane skeleton of gold(III)
and palladium(II) coordination complexes.4 Heterometallic
compounds based on gold(I) fragments have been reported for
titanocene,1,3,7,8 ruthenium(II),9−12 platinum(II),13 rhenium-
(I),14 and copper(II)10 derivatives.
We have reported on a number of titanocene−gold
derivatives with potential as anticancer agents (zero-, first-,
and second-generation derivatives 1−3 in Chart 1).1,3,8 We
described cytotoxic species in which gold fragments coordinate
to cyclopentadienyl−phosphane ligands that displayed a
synergistic effect (such as 1 in Chart 1).3 In order to improve
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Chart 1. Potential Anticancer Titanocene−Gold Complexes
Containing Different Linkers Described by Our Group1,3,8
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stability in physiological media and prevent the loss of
cyclopentadienyl−gold fragments, first-generation derivatives
(such as 2) were developed.8 While Ti−Cp hydrolysis still
occurs at pH 7, the gold fragment remains linked to titanium by
the carboxylate−phosphane ligand. These first-generation
compounds showed excellent activity against renal cancer cell
lines.8 In addition, the compounds were more selective toward
cancerous cells and lacked systemic toxicity in mice models.
A further and successful modification was the introduction of
a bifunctional ligand, mba (−OC(O)-p-C6H4-S−; derived from
4-mercaptobenzoic acid (H2mba)). We reported on com-
pounds of the type [(η5-C5H5)2TiMe(μ-mba)Au(PR3)] (sec-
ond generation such as 3 in Chart 1). Compound 3 was able to
block renal cancer growth both in vitro and in vivo by
pathway(s) that involve the inhibition of thioredoxin reductase
and decreased expression of protein kinases known to drive cell
migration.1 Preliminary evidence indicated that compound 3
may have appreciable anti-invasive properties. In addition, its
robustness was demonstrated in cellular uptake experiments on
Caki-1 cells by colocalization of Ti and Au metals in a 1:1
ratio.1
We aimed to exchange the gold(I)−phosphane fragments by
gold(I)−N-heterocyclic carbene moieties to improve or modify
the pharmacological profile of the previously reported
heterometallic complexes [(η5-C5H5)2TiMe(μ-mba)Au(PR3)]
(such as 3). NHC−gold(I) complexes are usually more stable
than gold(I)−phosphane compounds, display strong antimi-
tochondrial effects,15,16 and have demonstrated excellent
inhibitory properties of certain enzymes such as thioredoxin
reductase.15−23 They have also relevant anticancer effects in
vitro15−25 (including some recent examples on heterometallic
complexes9,10), and in vivo effects on melanoma have recently
been described.26 We report here on the synthesis, character-
ization, and stability studies of the novel monometallic gold−N-
heterocyclic carbene precursors [(NHC)Au(mbaH)] and
heterometallic titanocene complexes of the type [(η5-
C5H5)2TiMe(μ-mba)Au(NHC)]. We describe their in vitro
activity against human renal, prostate, colon, and breast cancer
cell lines and nontumorigenic human embryonic kidney cell
lines HEK-293T. In addition, we present studies of cellular
uptake, the effect of compounds on cell death, interactions with
DNA, inhibitory effects on thioredoxin reductase in vitro, and
antimigratory properties on PC3 prostate cancer cells.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. The synthesis of the
new monometallic gold(I)−NHC compounds bearing the
bifunctional ligand Hmba (Scheme 1) was carried out following
the same strategy reported for the synthesis of species
[Au(Hmba)(phosphane)].1
The thiol group on the bifunctional ligand H2mba (1 equiv)
was deprotonated by reaction with 1 equiv of KOH for 20 min
at room temperature. Subsequent addition of 1 equiv of the
gold(I) N-heterocyclic carbene complexes a−d in situ, in a
mixture of ethanol and water (4/1), led to the formation of the
corresponding monometallic gold complexes [Au(NHC)-
(Hmba)] (NHC = SIPr (4a), IPr (4b), IMes (4c), ICy
(4d)). Compounds 4a−d were isolated as pale orange solids in
high yield and characterized by NMR and UV−vis spectros-
copy, mass spectrometry, and elemental analysis (see the
Experimental Section). The chemical shifts of the carbene
carbons in the new derivatives (13C{1H} NMR spectra) appear
at fields lower (∼10 ppm) than those reported for the parent
chloro derivatives a−d,27,28 indicating a smaller electron-
donating character of the Hmba ligand (σ donor) with respect
to the chloride ligand (σ and π donor).
In the case of compound 4c, crystals suitable for X-ray
diffraction (Figure 1) were obtained by layering n-pentane over
a solution of compound 4c in tetrahydrofuran.
The crystals of compound 4c were determined to be triclinic
(space group P1 ̅) with Z = 4 formula units in the unit cell. The
environment of the gold atoms is close to linear (C−Au−S
177.76(18)°) (Figure 1). A selection of structural parameters is
given in Table 1. The individual monomeric units (Figure 1)
show hydrogen bonds (∼1.83 Å) between the carboxylic
groups of two neighboring units (Figure 2).
Scheme 1. Preparation of Monometallic Gold Complexes
[Au(NHC)(Hmba)] (NHC = SIPr (4a), IPr (4b), IMes (4c),
ICy (4d))
Figure 1. ORTEP view of the molecular structure of 4c showing the
labeling scheme. The labels for hydrogen and some carbon atoms are
omitted for clarity. A drawing of the molecular structure containing all
labeled carbon atoms is provided in the Supporting Information.
Table 1. Selected Structural Parameters of Complex 4c
Obtained from X-ray Single-Crystal Diffraction Studiesa
Au(1)−C(1) 1.995(6) N(1)−C(2) 1.381(8)
Au(1)−S(1) 2.2790(17) N(1)−C(21) 1.453(7)
S(1)−C(11) 1.746(6) N(2)−C(3) 1.382(7)
C(1)−N(1) 1.353(7) N(2)−C(31) 1.456(7)
C(1)−N(2) 1.341(7) C(2)−C(3) 1.335(9)
C(1)−Au(1)−S(1) 177.76(18) N(2)−C(1)−Au(1) 129.8(4)
C(11)−S(1)−Au(1) 105.92(19) N(1)−C(1)−Au(1) 126.0(4)
C(1)−N(1)−C(2) 111.4(5) C(1)−N(2)−C(3) 111.1(5)
C(1)−N(1)−C(21) 123.4(5) C(1)−N(2)−C(31) 124.8(4)
C(2)−N(1)−C(21) 125.2(5) C(3)−N(2)−C(31) 124.1(5)
N(2)−C(1)−N(1) 104.2(5) C(3)−C(2)−N(1) 106.2(5)
aBond lengths are given in Å and angles in deg.
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Similar gold(I) polymeric compounds reported by us1 and
others29 display additional Au−S interactions between the
dimeric units which are not present in the structure of 4c. This
fact might be related to the greater steric hindrance caused by
the presence of a bulkier ligand such as the NHC ligands
employed here.
The synthesis of the new heterometallic TiAu complexes is
depicted in Scheme 2. The reaction of 1 equiv of each of the
mononuclear gold(I) complexes 4a−d with 1 equiv of ([(η5-
C5H5)2TiMe2] afforded the corresponding heterobimetallic
complexes [([(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (NHC =
SIPr (5a), IPr (5b), IMes (5c), ICy (5d)), with concomitant
elimination of 1 equiv of methane. Compounds 5a−d were
obtained in moderate to high yields as air- and moisture-stable
yellow solids. These compounds are less acidic than titanocene
dichloride and soluble in DMSO/H2O, DMSO/PBS, or
DMSO/media (1/99) mixtures at micromolar concentrations,
which is relevant for subsequent biological testing. Moreover,
they are more soluble at higher concentrations in DMSO/PBS
mixtures than the previously described [(η5-C5H5)2TiMe(μ-
mba)Au(PR3)] counterparts. Compounds 5a−d are stable as
solids in air and at 5 °C for months and in CDCl3 solution for
at least 3 days. They are stable in DMSO-d6 solution for weeks.
The structures of complexes 5a−d depicted in Scheme 1
have been proposed on the basis of NMR and UV−vis
spectroscopy, mass spectrometry, and elemental analysis (see
the Experimental Section). Moreover, IR experiments and DFT
calculations were carried out in order to shed light on the
coordination mode of the carboxylate groups. The differences
found between the symmetric and antisymmetric stretching
bands for the carboxylate groups in the solid state IR spectra
(ranging from 210 to 351 cm−1) are greater than 200 cm−1,
indicating a monodentate coordination mode.30,31 DFT
calculations (e.g., Figure 3) also confirmed the monodentate
nature of the carboxylate functionality. In the Supporting
Information, data on different optimizations are provided. All
calculations performed led to the species containing a
monodentate carboxylate. Similar difference values (ranging
from 200 to 328 cm−1) were found between the symmetric and
antisymmetric stretching bands for the carboxylate groups in
the IR calculated on the basis of the DFT studies.
The stability of compounds 5a−d was evaluated by 1H NMR
spectroscopy in DMSO-d6 and DMSO-d6/PBS-D2O (3/2) and
by mass spectrometry over time (see the Supporting
Information). NMR experiments were performed in DMSO-
d6 and in DMSO-d6/PBS-D2O mixtures. The stability study of
compounds 5a−d by 1H NMR in DMSO-d6 showed half-life
values of 1, 3, 2, and 2 h, respectively: i.e., shorter than those for
the corresponding phosphane derivatives1 (3, Chart 1).
However, as shown in Table 2, compounds 5a−d exhibited
longer half-lives in 3/2 of DMSO-d6/PBS-D2O mixtures.
Titanocene dichloride is also known to hydrolyze with a
higher rate in DMSO than in water.32 Mass spectrometry
further supports the presence of species containing both
titanium and gold in 1% DMSO/PBS solution after 24 h (see
the Supporting Information).
Biological Activity. Assays of Cytotoxicity and Cell
Death. The cytotoxicity of the heterometallic complexes [(η5-
C5H5)2TiMe(μ-mba)Au(NHC)] (NHC = SIPr (5a), IPr (5b),
IMes (5c), ICy (5d)), monometallic gold(I) complexes
[Au(NHC)(Hmba)] (NHC = SIPr (4a), IPr (4b), IMes
(4c), ICy (4d) in Scheme 1), and titanocene Y33 used as
control was assayed by monitoring their ability to inhibit cell
growth using the PrestoBlue Cell Viability assay (see the
Experimental Section). The cytotoxic activity of the com-
pounds was determined as described in the Experimental
Section. In this assay, human cancer cell lines such as prostate
PC3 and DU145, renal Caki-1, colon DLL1, triple negative
breast MDA-MB-231, and nontumorigenic human embryonic
kidney cell lines HEK-293T were incubated with the indicated
compound for 72 h. The results are summarized in Table 3.
The heterometallic compounds are considerably more toxic
to the prostate cancer cell lines (PC3 and DU145) and the
colon cancer cell line (DLD1) than titanocene Y. In addition,
the heterometallic compounds 5a−d are more toxic in all the
cell lines (excluding the triple negative breast cancer cell lines)
Figure 2. ORTEP view of the polymeric structure of compound 4c
showing hydrogen bonds (green dotted line). The color code is as
given in Figure 1.
Scheme 2. Preparation of Heterometallic Titanocene−Gold
Complexes [(η5-C5H5)2Ti(CH3){OC(O)-p-
C6H4SAu(NHC)}] (NHC = SIPr (5a), IPr (5b), IMes (5c),
ICy (5d))
Figure 3. Optimized structures for heterometallic complexes 5a−d.
Table 2. Half-Lives (h) of Heterobimetallic Compounds 5a−
d in DMSO and in DMSO/PBS Mixtures by NMR
5a 5b 5c 5d
1H NMR, DMSO-d6 1 3 2 2
1H NMR, DMSO-d6 /PBS-D2O (3/2) 24 24 24 48
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than the monometallic gold compounds 4a−d on these cells.
None of the heterometallic or monometallic gold compounds
are toxic in the triple negative breast MDA-MB-231 cancer cell
lines in concentrations lower than 100 μM, as opposed to
titanocene Y. While the heterometallic compounds are toxic on
renal Caki-1 cancer cell lines, the IC50 values are only
comparable to those for titanocene Y for compounds 5a,c.
These IC50 values are larger than those found for the first-
generation titanocene−gold compounds previously described
by us8 and larger than the IC50 value of the second-generation
compounds of the type [(η5-C5H5)2TiMe(μ-mba)Au(PR3)]
1
(especially 3). In terms of selectivity, the heterometallic
compounds exhibit selectivity for the cancer cell lines
(excluding the triple negative breast cancer cell line, MDA-
MB-231), with compound 5b having a better selectivity in
comparison to nontumorigenic human embryonic kidney cell
lines HEK-293T. The new compounds display a better
selectivity toward the HEK-293T cell line than the phosphane
[(η5-C5H5)2TiMe(μ-mba)Au(PR3)] derivatives described be-
fore.
We did not find a strong correlation between the type of
NHC ligand employed and the biological activity.
Lysates of PC3 cells treated with 5a were analyzed by
inductively coupled plasma mass spectrometry (ICP-MS) to
determine the colocalization and amounts of Au and Ti metals
in these prostate cancer cell lines (see the Experimental Section
for details). Lysate of untreated cells was employed as a control.
It was observed that these cells have some basal levels of Au
present (0.1 μg Au per mg cell protein). The cellular uptake of
this compound increases with the increase in drug concen-
tration in the media, indicating a dose-dependent uptake of
compound 5a by PC3 cells (Figure 4).
Increasing the drug concentration from 10 to 20 μM resulted
in a 2.6-fold increase in the cellular levels of compound 5a.
More importantly, on correction for background levels of Au
and Ti in cell lysates, the stoichiometric ratios of these elements
were close to unity, suggesting that the compound remains
stable in the intracellular environment after 72 h (or that at
least uptake of both metals occurs concurrently).
We had found that the compound [(η5-C5H5)2TiMe(μ-
mba)Au(PPh3)] (3) exerted cell death by inducing apoptosis.
1
Titanocenes C, X, and Y are also known to induce apoptosis in
different cancer cell lines.34 In order to gain some insight into
the nature of the cytotoxicity of the new heterometallic
compounds containing N-heterocyclic carbenes, we performed
some experiments. The effect of titanocene Y, selected
monometallic compounds 4a,b, and bimetallic 5a,b on necrosis
and apoptosis on Caki-1 and PC3 was assessed by measuring
protease activity using non-cell-permeable substrates and cell-
permeable substrates and by measuring the total caspase-3 and
-7 activities with the ApoTox-Glo triplex assay (see the
Experimental Section). The effect of each treatment was
determined by comparing treated and untreated cells after 72 h
incubation. The results for each treatment were expressed as
fold changes between nontreated (0.1% DMSO) and treated
samples. ApoTox-Glo triplex assays were repeated twice (n =
2), and each repetition was run in quadruplicate.
The average of the four values was used for statistical
calculations. The data (Figure 5) are presented as the mean
value. It is important to note that, while all compounds are
represented at once in graphs in Figure 5, the amounts of
compound used to run the assays is different (according to
their different IC50 values). The lower amounts used (20 μM)
correspond to the new compounds 5a,b.
From these data, it can be deduced that compounds 5a,b
mainly induce apoptosis both in the renal Caki-1 and prostate
PC3 cancer cell lines in a way similar to that for titanocene Y
(highly apoptotic in vitro and in vivo34,35) and in the case of
compound 5a in Caki-1 and both 5a and 5b in PC3 with a
lower IC50 value. Titanocene Y was specially apoptotic on PC3
cancer cell lines. Monometallic compounds 4a,b were also
mainly apoptotic, but their IC50 values are considerably higher
than those of the new compounds 5a,b.
Migration Studies. In advanced tumors, increased cell
migration is a hallmark of cancer cell invasion and meta-
Table 3. IC50 Values (μM) in Human Cell Lines Determined with Heterometallic Ti−Au Compounds 5a−d, Monometallic Au
Compounds 4a−d, and Titanocene Y as Controla
compound PC3 DU-145 Caki-1 DLD1 MDA-MB-231 HEK-293T
titanocene Y 58.1 ± 11.2 55.2 ± 7.9 29.4 ± 4.2 56.2 ± 9.8 18.0 ± 3.6 >200
5a 9.8 ± 2.2 11.8 ± 3.0 21.0 ± 1.9 13.9 ± 1.7 >100 58.8 ± 6.7
5b 10.3 ± 2.8 18.9 ± 2.9 51.5 ± 3.7 30.4 ± 4.1 >100 >100
5c 17.1 ± 2.9 13.76 ± 2.7 29.11 ± 4.1 19.9 ± 4.1 >100 69.7 ± 9.9
5d 11.8 ± 1.6 16.7 ± 2.0 42.9 ± 5.8 21.5 ± 2.0 >100 77.1 ± 9.1
4a 66.3 ± 6.4 74.8 ± 4.4 81.4 ± 2.9 78.2 ± 6 >100 >100
4b 70.4 ± 6.8 60.9 ± 5.2 79.2 ± 11.7 82.6 ± 5.9 >100 >100
4c 57.1 ± 5.1 67.6 ± 7.1 97.2 ± 8.6 73.1 ± 9.6 >100 87.9 ± 6.4
4d 65.1 ± 4.4 59.9 ± 4.7 88.9 ± 5.1 77.5 ± 8.1 >100 97.2 ± 5.1
aAll compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture medium for a 72 h incubation period.
Figure 4. Cellular uptake of compound 5a in PC3 cells. The
concentrations of compound 5a calculated on the basis of Ti and Au
content in the cell lysates are similar, suggesting that the compound is
robust and that both elements are colocalized in the cells.
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stasis.36,37 The effect of titanocenes on the migratory capability
of cancer cells has been scarcely studied.38 We previously found
that first-generation [(η5-C5H5)2Ti{OC(O)-p-C6H4−
PPh2AuCl}2] (2)
8 and second-generation [(η5-C5H5)2TiMe-
(μ-mba)Au(PPh3)] (3)
1 titanocene−gold complexes displayed
relevant antimigratory properties.1 We evaluated the anti-
invasive properties of the most active heterometallic complexes
[(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (NHC = SIPr (5a), IPr
(5b)) and titanocene Y, by using the same wound-healing
scratch assay (Experimental Section) on prostate cancer PC3
cell lines. Twenty-four hours following a scratch through an in
vitro confluent monolayer of prostate carcinoma PC3, cells
treated with 15 μM titanocene Y invaded 69% of the scratch
and cells treated with 5 μM of 5a or 5b invaded 42% or 33% of
the scratch, respectively, while cells treated with 0.1% DMSO
control invaded 88% of the scratch (Figure 6A). Figure 6B
shows a comparison in terms of total reduction of migration
among compounds 5a,b and titanocene Y. A similar assay was
performed with gold monometallic compounds 4a,b (see
Figure S60 in the Supporting Information), and it was found
that under the same conditions (in vitro confluent monolayer
of prostate carcinoma PC3 cells treated with 15 μM of the gold
monometallic compounds) 4a,b invaded 73% and 80% of the
scratch, respectively.
We can conclude from this experiment that heterometallic
compounds 5a,b possess antimigratory properties in PC3 cells
in comparison to the control and are twice as powerful in
inhibiting migration as titanocene Y. Recently enantiopure
cyclopentadienyl Ti(IV) oximato compounds have been shown
to affect the cell adhesion and migration of PC3 cancer cell
lines.39 In this case the compounds (50 μM) showed a
migration capability (62−72% of wound healing) significantly
lower than that of control cells. The heterometallic complexes
described here (5a,b) thus have strong antimigratory properties
on PC3 cancer cell lines.
Interaction with Plasmid pBR322 DNA.We and others have
previously found that titanocene−gold compounds interact
weakly with calf thymus DNA or do not interact with plasmid
pBR322 DNA, as is the case for many other gold
compounds.1,3,7,8 Recent reports on titanocene dichloride and
titanocene Y also indicate a weak interaction with DNA40,41 and
the lack of suppression for DNA-processing enzymes.40 DNA
interactions were tested with heterometallic compounds 5a−d
or cisplatin by using plasmid (pBR322) DNA (Figure 7). This
plasmid has two main forms: OC (open circular or relaxed
form, form II) and CCC (covalently closed or supercoiled
form, form I). Agarose gel electrophoresis assays were
performed whereby decreased electrophoretic mobilities of
both forms were taken as evidence of metal−DNA binding.
Figure 5. (A) Impairment of the viability of Caki-1 cells by
compounds 4a (80 μM), 5a (20 μM), 4b (80 μM) 5b (50 μM),
and titanocene Y (30 μM) by inducing apoptosis. (B) Impairment of
the viability of PC3 cells by compounds 4a (60 μM), 5a (10 μM), 4b
(70 μM), 5b (10 μM), and titanocene Y (30 μM) by inducing
apoptosis.
Figure 6. Cell migration in 5a or 5b treated PC3 cells. Migration of
PC3 cells was assessed using a wound-healing assay following
treatment with 15 μM titanocene Y or 5 μM of 5a or 5b incubated
for 24 h (values normalized against 0.1% DMSO control): (A)
absolute migration (%); (B) reduction of migration (%).
Figure 7. Electrophoresis mobility shift assays for cisplatin and
heterometallic Ti−Au compounds 5a−d (see the Experimental
Section for details). DNA refers to untreated plasmid pBR322. a, b,
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Generally, the slower the mobility of supercoiled DNA (CCC,
form I), the greater the DNA unwinding produced by the
drug.42 For example, binding of cisplatin to plasmid DNA
results in decreased mobility of the CCC form and increased
mobility of the OC form. Treatment of plasmid DNA with
increasing amounts of the new heterometallic compounds 5a−
d did not affect the mobility of the faster-running supercoiled
form (form I) even at the highest molar ratios (d). This result is
in accordance with the lack of interaction shown by
titanocene−gold compounds (zero, first, and second gener-
ation) and the lack of interaction displayed by monometallic
gold compounds 4a−d (see Figure S59 in the Supporting
Information).
Inhibition of Thioredoxin Reductase in PC3 Cancer Cells.
Many chemoresistant cancers produce changes in the cell
antioxidant capacity. The overexpression of thioredoxin
reductase (TrRx) is among the key defense and survival
mechanisms of cisplatin-resistant cells. Thioredoxin reductase
has become a potential target in cancer chemotherapy.43,44 We
have reported on the inhibition of TrRx in Caki-1 cells by
auranofin and the heterometallic titanocene−gold complex
[(η5-C5H5)2TiMe(μ-mba)Au(PR3)] (3).
1 Since Au−NHC
compounds are known to inhibit TrRx, we measured the
activity of thioredoxin reductase in PC3 prostate cancer cells,
following incubation with monometallic compounds [Au-
(NHC)(Hmba)] (NHC = SIPr (4a), IPr (4b)) and bimetallic
compounds [(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (NHC =
SIPr (5a), IPr (5b)). We found thioredoxin reductase activity
to be lower in cells treated with 5 μM of 5a and 5b with
observed inhibitions of 31% and 30%, respectively, after a 5 h
incubation period (Figure 8). The inhibition was 61% (5a) and
76% (5b) after 24 h incubation. In the case of PC3 cells treated
with 30 μM of monometallic gold compounds (4a,b) there was
inhibition of thioredoxin reductase but to a lower extent (30%
and 36% for 4a and 4b, respectively, after 24 h incubation).
Surprisingly, we found that titanocene Y (15 μM) was also a
strong TrRx inhibitor in PC3 cells (with a 57% or 80%
reduction after 5 or 24 h of treatment, respectively, see Figure
S61 in the Supporting Information). This experiment showed
that the inhibition of TrRx is involved in the cell death
mechanism of the new compounds and that the titanocene
component has an influence on this target, although other
cellular targets may not be excluded. In the past years, a
number of other targets (such as gluthatione reductase, cysteine
proteases such as cathepsins K and S, protein thyrosine
phosphatases, glutathione peroxidase (GPx),44 iodothyronine
deiodinase (ID),45 and IkB kinase) have been identified for
gold(I) complexes.15 Helicases/topoisomerases and HIST1H4
core histones have been pointed out as targets of titanocene
C,45 and we reported on the strong inhibitory effect of
titanocene dichloride against PI3 protein kinases from a panel
of 35 kinases of oncological interest.8
For titanocene−gold(I) heterometallic complexes, we have
shown that the compound [(η5-C5H5)2TiMe(μ-mba)Au(PR3)]
(3) not only inhibited TrRx in Caki-1 renal cancer cells with an
IC50 value very similar to that of Auranofin but also was
considerably more cytotoxic than auranofin in this cell line due
to a more potent inhibition of the specific protein kinases AKT,
p90-RSK, and MAPKAPK3 in vitro.1
All of these results warrant further studies on the mode of
action of the new heterometallic compounds.
■ CONCLUSIONS
In conclusion, we have described the preparation of novel
heterometallic titanocene−gold compounds incorporating gold-
(I)−N-heterocyclic carbene fragments. The exchange of the
phosphane ligands by NHC ligands (L) in complexes of the
type [(η5-C5H5)2TiMe(μ-mba)Au(L)] did result in lower IC50
values in renal Caki-1 cancer cell lines, although a significant
activity and a considerably higher selectivity with respect to
noncancerous cell lines was obtained in prostate and colon
cancer cell lines for the new Ti−Au−NHC complexes. As for
the analogous titanocene−gold compounds containing phos-
phanes, the new heterometallic carbene derivatives did not
display a significant interaction with plasmid (pBR322) used as
a model nucleic acid. Two selected compounds (5a,b) were
found to be highly apoptotic and to inhibit TrRx in prostate
PC3 cancer cell lines. These complexes also display strong
antimigratory properties. The work presented here is the proof
of concept that the substitution of PR3−gold(I) by NHC−
gold(I) fragments in titanocene−gold complexes may afford
derivatives with potential as cancer chemotherapeutics which
will allow for further modification. With the NHC ligands
described in this work we did not find a strong SAR correlation.
Further optimization of the NHC ligands employed and more
detailed mechanistic studies are needed in order to find
candidates with improved pharmacological properties. These
studies are currently under way in our laboratories.
Figure 8. Thioredoxin reductase activity in 4a, 4b, 5a, or 5b treated
PC3 cells: (A) activity of endogenous PC3 thioredoxin reductase from
soluble whole cell lysates following incubation with 30 μM of 4a or 4b
for 5 and 24 h (values normalized against DMSO control); (B) activity
of endogenous PC3 thioredoxin reductase from soluble whole cell
lysates following incubation with 5 μM of 5a or 5b for 5 h and 24 h
(values normalized against DMSO control).
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■ EXPERIMENTAL SECTION
Chemistry. Synthesis and Characterization: General Procedure.
Imidazolium salts (SiPr·HCl,46 IPr·HCl,46 IMes·HCl,47 ICy·HCl48),
[AuCl(tht)],49 [AuCl(NHC)] (NHC = SIPr (1),24 IPr (2),24 IMes
(3),28 ICy (4)28), and titanocene Y33 were prepared as previously
reported. Cp2TiCl2 and H[AuCl4] were purchased from Strem
Chemicals. Tetrahydrothiophene was purchased from Sigma-Aldrich.
All purchased reactants were used without further purification.
Reaction solvents were purchased anhydrous from Fisher Scientific
(ACS grade) and purified by use of a PureSolv purification unit from
Innovative Technology, Inc. Deuterated solvents were purchased from
Cambridge Isotope Laboratories, Inc., kept over molecular sieves (3 Å,
beads, 4−8 mesh), and degassed by the freeze−pump−thaw method.
NMR spectra were recorded using a Bruker AV400 (1H NMR at 400
MHz, 13C{1H} NMR at 100.6 MHz). Chemical shifts (δ) are given in
ppm using CDCl3 as the solvent, unless otherwise stated.
1H and 13C
NMR resonances were measured relative to solvent peaks considering
tetramethylsilane at 0 ppm. Coupling constants J are given in hertz. IR
spectra (4000−250 cm−1) were recorded on a Nicolet 6700 Fourier
transform infrared spectrophotometer on samples in the solid state
(ATR accessory). Elemental analyses were performed on a
PerkinElmer 2400 CHNS/O series II analyzer by Atlantic Microlab
Inc. (US). Mass spectra (electrospray ionization, ESI-high resolution)
were performed on a Waters Q-Tof Ultima instrument. The
theoretical isotopic distributions have been calculated using enviPat
Web 2.0.1. Stability studies were performed in a Cary 100 Bio UV−
visible spectrophotometer. The pH was measured in an OAKTON pH
conductivity meter in 5 × 10−5 M 1/99 DMSO/H2O solutions.
[Au(Hmba)(NHC)] (4a−d). H2mba (0.154 g, 1 mmol) was added to
a solution of KOH (0.056 g, 1 mmol) in 20 mL of ethanol (16 mL)
and water (4 mL) and stirred for 20 min at room temperature.
Afterward, the corresponding [Au(NHC)Cl] (1 mmol) was added to
the solution and the mixture was stirred for 5 h. The solvents were
then removed under reduced pressure, and the residue was washed
with water (3 × 2 mL) and then diethyl ether (3 × 3 mL) to afford
compounds 4a−d as white powdery solids.
4a (NHC = SIPr): 74% yield (0.548 g). Anal. Calcd for
C34H43AuN2O2S (740.75): C, 55.13; H, 5.85; N, 3.78; S, 4.33.
Found: C, 55.03; H, 5.73; N, 3.88; S, 4.06. 1H NMR (CDCl3): δ 1.36
(d, 3JHH = 6.9 Hz, 12H, CH(CH3)2), 1.41 (d,
3JHH = 6.8 Hz, 12H,
CH(CH3)2), 3.12 (m, 4H, CH(CH3)2), 4.09 (s, 4H, CH2-imidazole),
6.74 (d, 3JHH = 8.3 Hz, 2H, ArH), 7.30 (d,
3JHH = 7.8 Hz, 4H, ArH),
7.42 (d, 3JHH = 8.3 Hz, 2H, ArH), 7.52 (t,
3JHH = 7.8 Hz, 2H, ArH).
13C{1H} NMR (CDCl3): δ 24.57 (s, CH(CH3)2), 25.41 (s,
CH(CH3)2), 29.40 (s, CH(CH3)2), 53.99 (s, CH2-imidazole), 122.44
(s, 2-C6H3), 125.02 (s, 3-C6H3), 129.36 (s, 3-C6H4), 130.41 (s, 4-
C6H3), 131.50 (s, 2-C6H4), 134.35 (s, 1-C6H3), 147.28 (s, 4-C6H4),
154.69 (s, 1-C6H4), 171.04 (s, C = O), 205.68 (s, C-carbene). IR
(cm−1): 2962 m,br (OH), 2360 m, 1671 s, 1585 s (νasym CO2), 1338 s,
1289 vs (νsym CO2), 1175 m, 1086 m, 759 m. MS (ESI+) [m/z]:
847.36 (100%) [M]+.
4b (NHC = IPr): 96% yield (0.709 g). Anal. Calcd for
C34H41AuN2O2S (738.73): C, 55.28; H, 5.59; N, 3.79; S, 4.34.
Found: C, 55.32; H, 5.64; N, 3.77; S, 4.10. 1H NMR (CDCl3): δ 1.24
(d, 3JHH = 6.9 Hz, 12H, CH(CH3)2), 1.34 (d,
3JHH = 6.8 Hz, 12H,
CH(CH3)2), 2.62 (m, 4H, CH(CH3)2), 6.88 (d,
3JHH = 8.3 Hz, 2H,
ArH), 7.22 (s, 2H, CH-imidazole), 7.35 (d, 3JHH = 7.8 Hz, 4H, ArH),
7.46 (d, 3JHH = 8.3 Hz, 2H, ArH), 7.59 (t,
3JHH = 7.8 Hz, 2H, ArH).
13C{1H} NMR (CDCl3): δ 24.44 (s, CH(CH3)2), 24.79 (s,
CH(CH3)2), 29.23 (s, CH(CH3)2), 122.53 (s, 2-C6H3), 123.31 (s,
CH-imidazole), 124.65 (s, 3-C6H3), 129.39 (s, 3-C6H4), 131.11 (s, 4-
C6H3), 131.58 (s, 2-C6H4), 134.34 (s, 1-C6H3), 146.23 (s, 4-C6H4),
154.98 (s, 1-C6H4), 171.27 (s, CO), 186.36 (s, C-carbene). IR
(cm−1): 2958 m,br (OH), 2361 w, 1677 s, 1585 s (νasym CO2), 1285 m
(νsym CO2), 1176 m, 1088 m, 759 m.
4c (NHC = IMes): 88% yield (0.576 g). Anal. Calcd for
C28H29AuN2O2S (654.57): C, 51.38; H, 4.47; N, 4.28; S, 4.90.
Found: C, 51.41; H, 4.45; N, 4.25; S, 4.99. 1H NMR (CDCl3): δ 2.15
(s, CH3, 12H), 2.41 (s, 6H, CH3), 7.02 (d,
3JHH = 8.4 Hz, 2H, ArH),
7.06 (s, 4H, ArH), 7.14 (s, 2H, CH-imidazole), 7.50 (d, 3JHH = 8.4 Hz,
2H, ArH). 13C{1H} NMR (CDCl3): δ 18.14 (s, CH3), 21.64 (s, CH3),
122.38 (s, CH-imidazole), 122.67 (s, 4-C6H2), 129.38 (s, 2-C6H4),
129.81 (s, 3-C6H2), 135.06 (s, 2-C6H2), 135.32 (s, 1-C6H2), 140.27 (s,
4-C6H4), 154.68 (s, 1-C6H4), 170.40 (s, CO), 184.56 (s, C-
carbene). IR (cm−1): 2948 m,br (OH), 1668 vs, 1583 s (νasym CO2),
1411 m, 1283 vs (νsym CO2), 1170 m, 1087 m, 767 m.
4d (NHC = ICy): 78% yield (0.454 g). Anal. Calcd for
C22H29AuN2O2S (582.51): C, 45.36; H, 5.02; N, 4.81; S, 5.50.
Found: C, 45.20; H, 5.04; N, 4.73; S, 5.45. 1H NMR (CDCl3): δ
1.21−2.16 (m, 20H C6H11), 4.61 (tt, 2H, 3JHH = 12.1, 3.8 Hz C6H11),
6.97 (s, 2H, CH-imidazole), 7.72 (d, 3JHH = 8.4 Hz, 2H, ArH), 7.78 (d,
3JHH = 8.4 Hz, 2H, ArH).
13C{1H} NMR (CDCl3): δ 25.47 (s, 4-
C6H11), 25.79 (s, 3-C6H11), 34.57 (s, 2-C6H11), 61.27 (s, 1-C6H11),
117.35 (s, CH-imidazole), 123.36 (s, 4-C6H4), 129.84 (s, 2-C6H4),
132.28 (s, 3-C6H4), 154.46 (s, 1-C6H4), 170.60 (s, CO), 179.90 (s,
C-carbene). IR (cm−1): 2932 m,br (OH), 2357 w, 1677 s, 1581 s
(νasym CO2), 1417 s, 1287 vs (νsym CO2), 1083 m, 766 m.
[(η5-C5H5)2TiMe(μ-mba)Au(NHC)] (5a−d). The corresponding
monometallic gold complex 4a−d (0.41 mmol) was dissolved in
tetrahydrofuran (15 mL) and added via cannula over a solution of
Cp2TiMe2 (0.084 g, 0.41 mmol) in toluene (5 mL) to give rise to a
bright orange solution that was stirred for 1.5 h at room temperature.
The solution was filtered off, and the solvents were then removed
under reduced pressure to afford an oily solid that was washed with a
dichloromethane/diethyl ether/hexane mixture (2/6/2) (3 × 5 mL).
The heterometallic complexes were then isolated as orange solids.
5a (NHC = SIPr): 62% yield (0.237 g). Anal. Calcd for
C45H55AuN2O2STi·H2O (950.84): C, 56.84; H, 6.04; N, 2.95; S,
3.37. Found: C, 57.15; H, 6.15; N, 2.62; S, 3.02. 1H NMR (CDCl3): δ
0.99 (s, 3H, Ti-CH3), 1.35 (d,
3JHH = 6.9 Hz, 12H, CH(CH3)2), 1.41
(d, 3JHH = 6.8 Hz, 12H, CH(CH3)2), 3.11 (m, 4H, CH(CH3)2), 4.08
(s, 4H, CH-imidazole), 6.19 (s, 10H, Cp), 6.64 (d, 3JHH = 8.5 Hz, 2H,
ArH), 7.05 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.28 (d,
3JHH = 7.8 Hz, ArH,
4H), 7.50 (t, 2H, 3JHH = 7.7 Hz, ArH).
13C{1H} NMR (CDCl3): δ
24.24 (s, CH(CH3)2), 25.06 (s, CH(CH3)2), 29.05 (s, CH(CH3)2),
43.73 (s, Ti-CH3, 53.63 (s, CH-imidazole), 114.62 (s, Cp), 125.00 (s,
3-C6H3), 127.21 (s, 2-C6H3), 129.19, (s, 3-C6H4), 130.37 (s, 4-C6H3),
131.17 (s, 2-C6H4), 134.41 (s, 1-C6H3), 147.24 (s, 4-C6H4), 150.87 (s,
1-C6H4), 172.35 (s, CO), 206.00 (s, C-carbene). IR (cm−1): 2959 m
(Cp), 1585 s (νasym CO2), 1493 s, 1275 vs (νsym CO2), 1169 m (Cp),
1085 m (Cp). pH 5.92.
5b (NHC = IPr): 68% yield (0.259 g). Anal. Calcd for
C45H53AuN2O2STi·H2O (948.83): C, 56.96; H, 5.84; N, 2.95; S,
3.38. Found: C, 57.41; H, 5.73; N, 2.94; S, 3.39. 1H NMR (CDCl3): δ
0.99 (s, 3H, Ti-CH3), 1.23 (d,
3JHH = 6.9 Hz, 12H, CH(CH3)2), 1.33
(d, 3JHH = 6.8 Hz, 12H, CH(CH3)2,), 2.61 (m, 4H, CH(CH3)2), 6.20
(s, 10H, Cp), 6.78 (d, 3JHH = 8.4 Hz, 2H, ArH), 7.09 (d,
3JHH = 8.3 Hz,
2H, ArH), 7.21 (s, 2H, CH-imidazole), 7.33 (d, 3JHH = 7.8 Hz, 4H,
ArH), 7.58 (t, 3JHH = 7.8 Hz, 2H, ArH).
13C{1H} NMR (CDCl3): δ
24.47 (s, CH(CH3)2), 24.79 (s, CH(CH3)2), 29.23 (s, CH(CH3)2),
44.07 (s, Ti-CH3, 114.28 (s, Cp), 123.24 (s, CH-imidazole), 124.63 (s,
3-C6H3), 127.25 (s, 2-C6H3), 129.22 (s, 3-C6H4), 131.07 (s, 4-C6H3),
131.26 (s, 2-C6H4), 134.40 (s, 1-C6H3), 146.21 (s, 4-C6H4), 151.13 (s,
1-C6H4), 172.36 (s, CO), 186.77 (s, C-carbene). IR (cm−1): 2959 m
(Cp), 2361 w, 1636 m, 1584 s (νasym CO2), 1469 m, 1286 vs (νsym
CO2), 1169 m (Cp), 1085 m (Cp). pH 6.16.
5c (NHC = IMes): 81% yield (0.281 g). Anal. Calcd for
C39H41AuN2O2STi (846.65): C, 55.33; H, 4.88; N, 3.31; S, 3.79.
Found: C, 55.22; H, 4.92; N, 3.19; S, 3.58. 1H NMR (CDCl3): δ 0.98
(s, 3H, Ti-CH3), 2.14 (s, 12H, CH3), 2.41 (s, 6H, CH3), 6.19 (s, 10H,
Cp), 6.94 (d, 3JHH = 8.4 Hz, 2H, ArH), 7.04 (s, 4H, ArH), 7.13 (s, 2H,
CH-imidazole), 7.15 (d, 3JHH = 8.4 Hz, 2H, ArH).
13C{1H} NMR
(CDCl3): δ 18.15 (s, CH3), 21.63 (s, CH3), 44.28 (s, Ti-CH3), 114.28
(s, Cp), 122.31 (s, CH-imidazole), 122.49 (s, 4-C6H2), 129.23 (s, 2-
C6H4), 129.39 (s, 3-C6H2), 131.58 (s, 2-C6H2), 135.27 (s, 1-C6H2),
140.19 (s, 4-C6H4), 150.66 (s, 1-C6H4), 172.28 (s, CO), 184.88 (s,
C-carbene). IR (cm−1): 2954 m (Cp), 1631 w, 1584 m (νasym CO2),
1286 vs (νsym CO2), 1168 m (Cp), 1085 m (Cp). pH 6.15.
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5d (NHC = ICy): 79% yield (0.250 g). Anal. Calcd for
C33H41AuN2O2STi·H2O (792.60): C, 50.01; H, 5.47; N, 3.53; S,
4.05. Found: C, 50.01; H, 5.31; N, 3.45; S, 4.03. 1H NMR (CDCl3): δ
0.96 (s, 3H, Ti-CH3) 1.21−2.16 (m, 20H, C6H11), 4.61 (m, 2H,
C6H11), 6.19 (s, 10H, Cp), 6.96 (s, 2H, CH-imidazole), 7.39 (d,
3JHH =
8.4 Hz, 2H, ArH), 7.62 (d, 3JHH = 8.4 Hz, 2H, ArH).
13C{1H} NMR
(CDCl3): δ 25.50 (s, 4-C6H11), 25.79 (s, 3-C6H11), 34.54 (s, 2-C6H11),
44.20 (s, Ti-CH3), 61.20 (s, 1-C6H11), 114.64 (s, Cp) 117.28 (s, CH-
imidazole), 128.21 (s, 4-C6H4), 129.67 (s, 2-C6H4), 132.06 (s, 3-
C6H4), 150.47 (s, 1-C6H4), 172.27 (s, CO), 180.19 (s, C-carbene).
IR (cm−1): 2931 m (Cp), 1636 m, 1584 m (νasym CO2), 1285 vs (νsym
CO2), 1168 m (Cp), 1084 m (Cp). pH 5.82.
X-ray Crystallography. Suitable single crystals of compound 4c
were obtained by layering pentane over a solution of tetrahydrofuran.
Details of the crystallographic data and a complete list of selected
structural parameters are given in Tables S1 and S2 in the Supporting
Information, respectively. The crystal was mounted on a glass fiber,
and the diffraction measurements were performed with a Nonius
Kappa CCD area-detector diffractometer with Mo Kα radiation (λ =
0.71073 Å). The structure were solved by direct methods and refined
by least-squares techniques on weighted F2 values for all reflections
(SHELXTL, 6.14). All non-hydrogen atoms were assigned anisotropic
displacement parameters and refined without positional constraints.
All hydrogen atoms were calculated with a riding model. Complex
neutral-atom scattering factors were used. The program SQUEEZE, a
part of the Platon2 package of crystallographic software, was used to
calculate the solvent disorder area and remove its contribution to the
overall intensity data. These data can be obtained free of charge from
The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.
uk/data_request/cif. The assigned deposition number at the Cam-
bridge Crystallographic Data Centre for compound 4c is 1438894.
DFT Calculations. The calculations have been performed using the
hybrid density functional method B3LYP,50,51 as implemented in
Gaussian09.52 Geometries were optimized with the 6-311G(d) basis
set for the P and S elements, the 6-31G(d,p) basis set for the C, N, P,
S, and H elements, and the SDD pseudopotential for the titanium,
iron, and gold metal centers.53,54 Frequency calculations have been
done at the same level of theory as the geometry optimizations to
confirm the nature of the stationary points.
Biology. Interactions of the New Compounds with Plasmid
pBR322 (Gel Electrophoresis Mobility Shift Assay). Ten microliter
aliquots of pBR322 plasmid DNA (20 μg/mL) in buffer (5 mM Tris/
HCl, 50 mM NaClO4, pH 7.39) were incubated with different
concentrations of the compounds (4a−d, 5a−d, and cisplatin as
control) (in the range 0.25 and 4.0 metal complex to DNA bp) at 37
°C for 20 h in the dark. Samples of free DNA and cisplatin-DNA were
prepared as controls. After the incubation period, the samples were
loaded onto the 1% agarose gel. The samples were separated by
electrophoresis for 1.5 h at 80 V in Tris-acetate/EDTA buffer (TAE).
Afterward, the gel was stained for 30 min with a solution of GelRed
nucleic acid stain.
Cell Culture and PrestoBlue Cell Viability Assay for Caki-1, DLD-1,
PC3, DU145, MDA-MB 231, and HEK-293T Cells. Human renal clear-
cell carcinoma Caki-1, human breast adenocarcinoma cells MDA-MB-
231, human prostate adenocarcinoma cells PC3, human prostate
carcinoma cells DU145, and the human colorectal adenocarcinoma
cells DLD-1 in comparison with healthy human embryonic kidney
cells HEK-293T were used to study the cytotoxic activity of bimetallic
carbenes 5a−d and their monometallic controls 4a−d. The cells were
all obtained from the American Type Culture Collection (ATCC)
(Manassas, VA). All of the cells were grown adherently. The Caki-1,
PC3, Du145, and DLD-1 cells were cultured in Roswell Park Memorial
Institute (RPMI-1640) (Mediatech Inc., Manassas, VA) medium,
while MDA-MB-231 and HEK-293T cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) (Mediatech Inc.,
Manassas, VA); all media were supplemented with 10% fetal bovine
serum (FBS, Life Technologies, Grand Island, NY), 1% Minimum
Essential Media (MEM) nonessential amino acids (NEAA, Medi-
atech), and 1% penicillin−streptomycin (Pen Strep, Mediatech). All
cells were cultured at 37 °C under 5% CO2 and 95% air in a
humidified incubator. For evaluation of cell viability, cells were seeded
at a concentration of 5 × 103 cells/well in 90 μL of DMEM or RPMI
without phenol red and without antibiotics, supplemented with 10%
FBS and 2 mM L-glutamine into tissue culture grade 96-well flat
bottom microplates (BioLite Microwell Plate, Fisher Scientific,
Waltham, MA) and grown for 24 h at 37 °C under 5% CO2 and
95% air in a humidified incubator. All compounds were dissolved in
DMSO and diluted to 1% in media before addition to cell culture
medium. The intermediate dilutions of the compounds were added to
the wells (10 μL) to obtain concentrations of 1, 10, and 100 μM, 0.1%
DMSO was used as control, and the cells were incubated for 72 h.
PrestoBlue was used to quantitatively measure variations in cell
viability of treated cells. Following 72 h drug exposure, 11 μL of per
well of 10× PrestoBlue (Life Technologies, Carlsbad, CA) labeling
mixture was added to the cells at a final concentration of 1× and
incubated for 1.5 h at 37 °C under 5% CO2 and 95% air in a
humidified incubator. The optical absorbance of each well in a 96-well
plate was quantified using a 16 BioTek ELx 808 absorbance microplate
reader (BioTek Winooski, VT) set at 570 nm excitation and 600 nm
emission wavelength. The percentage of surviving cells was calculated
from the ratio of absorbance of treated to untreated cells. The IC50
(μM) value was calculated as the concentration reducing the
proliferation of the cells by 50% and is presented as a mean
(±S.EM) of at least two independent experiments each with triplicate
measurements.
Stability of Compound 5a in Vitro and Colocalization of Ti/Au
Metals in PC3 Cells. PC3 cells were incubated with 10 and 20 μM
compound 5a for 72 h. Postincubation, the cells were washed twice
with cold PBS and lysed with cell lysis buffer comprising of 1% (v/v)
Triton-X-100, 25 mM HEPES, 100 mM NaCl, 1 mM EDTA, 10% (v/
v) glycerol, and protease and phosphatase inhibitors. Lysates from
untreated cells incubated with media supplemented with DMSO for
the same duration were used as controls. Gold and titanium contents
in the cell lysates were determined using ICP-MS. One hundred
microliter portions of lysates were transferred into a glass vials, and 1
mL of concentrated acid mix (comprised of 75% of 16 N nitric acid
and 25% of 12 N hydrochloric acid) was added. The mixture was
heated at 90 °C for 5 h. After cooling, the samples were diluted with
water and 40 ppb of indium internal standard was added and analyzed
in a Thermo Scientific XSERIES 2 ICP-MS with ESI PC3 Peltier
cooled spray chamber with an SC-FAST injection loop and SC-4
autosampler. All of the elements were analyzed using He/H2 collision-
reaction mode. A standard curve (0, 1, 5, 10, and 20 μM) of
compound 5a was processed similarly to determine the linearity of
extraction efficiency of Au and Ti. The protein contents of the cell
lysates were determined using a bicinchoninic acid based protein assay
kit (Thermo Scientific). The final levels of either Ti or Au were
normalized to the cellular protein levels.
Cell Death for Titanocene Y, 4a,b, and 5a,b. For apoptosis,
viability, and necrosis assays, the Caki-1 and PC3 cells were seeded in
96-well opaque-walled tissue culture plates with clear bottoms
(Thermo Scientific Nunc; Somerset, NJ) at an initial density of 5 ×
104 red and without antibiotics, supplemented with 10% FBS and 2
mM L-glutamine. Following 24 h incubation, Caki-1 cells were treated
with 30 μM of titanocene Y, 80 μM of compounds 4a and 4b, and and
10 μM of 5a or 5b for 72 h, while PC3 cells were treated with 30 μM
of titanocene Y, 60 μM of 4a, 70 μM of 4b, and 10 μM of 5a or 5b for
72 h. The cells were then assayed using the ApoTox-Glo triplex assay
(Promega GmbH, High-Tech-Park, Mannheim, Germany). Twenty
microliter portions of viability/cytotoxicity reagent containing both
glycylphenylalanyl-aminofluorocoumarin (GF-AFC) and bis-alanyla-
lanyl-phenylalanyl-rhodamine 110 (bis-AAF-R110) substrates were
added to each well, and they were briefly mixed by orbital shaking at
200 rpm for 30 s and then incubated at 37 °C for 2 h. Fluorescence
was measured at 400 nm for excitation/505 nm for emission (viability)
and 485 nm for excitation/520 nm for emission (cytotoxicity/
necrosis) using a BioTek Fluorescence Microplate Reader (BioTek
U.S., Winooski, VT)). Next, 100 μL of Caspase-Glo 3/7 reagents was
added to each well, and the samples were briefly mixed by orbital
shaking at 200 rpm for 30 s and then incubated at room temperature
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for 1 h. Luminescence was measured for 1 s and is proportional to the
amount of caspase activity present (BioTek U.S., Winooski, VT). The
results for each treatment were expressed as fold change between
nontreated (0.1% DMSO) and treated samples. ApoTox-Glo triplex
assays were repeated twice (n = 2), and each repetition was run in
quadruplicate. The average of the four values was used for statistical
calculations. The data are presented as the mean values.
In Vitro Migration Assay (Wound Healing Assay). For the
assessment of cell migration, confluent PC3 cells maintained in
standard medium were wounded with a plastic micropipette tip (tip
20−200 μL). After washing, the medium was replaced by fresh
medium containing 5 μM of either 5a or 5b, 15 μM of titanocene Y,
and 15 μM of 4a or 4b or 0.1% DMSO solution (control).
Photographs of the wounded area were taken after 0 and 24 h using
phase-contrast microscopy. For evaluation of wound closure, four
randomly selected points along each wound area were marked and the
horizontal distance of migrating cells from the initial wound was
measured (Labomed TCM400 Inverted Phase Microscope Series,
equipped with a digital camera (Fisher Scientific Moticam 10). The
assays were done twice, and for each trial two images were analyzed
per time point.
Method for Thioredoxin Reductase Activity Assay. Whole cell
lysates was assayed using PC3 cells treated in vitro with 5 μM of 5a or
5b, 15 μM of titanocene Y, 30 μM of 4a or 4b, or 0.1% DMSO
solution (control). After 5 or 24 h of treatment, cells were washed
three times in PBS and lysed by douncing using scrappers and sheer
force through a syringe with a 34 gauge in assay buffer (Abcam
Thioredoxin Reductase Assay kit, ab83463) with 1 mM Protease
Inhibitor Cocktail (Abcam, ab65621). The lysates were centrifuged at
10000 rcf for 15 min at 4 °C to isolate insoluble material. The total
protein concentrations of soluble lysates were measured using the
Bradford assay. The soluble lysates were incubated for 20 min in assay
buffer or assay buffer with a proprietary thioredoxin reductase specific
inhibitor before adding a specific substrate, DTNB (5,5′-dithiobis(2-
nitrobenzoic acid)), and measuring the activity at 1 min intervals for
30 min using a BioTek Fluorescence Microplate Reader (BioTek U.S.,
Winooski, VT) at λ 412 nm. Lysates were tested in duplicate. TrxR
activity was calculated on the basis of the linear amount of TNB (2-
nitro-5-thiobenzoic acid) produced per minute per milligram of total
protein and adjusted for background activity from enzymes other than
TrxR in the lysates.
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